Genentech National Cooperative Growth Study Surveillance Program for Nutropin AQ, Nutropin, and Protropin
Information source: Emory University
Information obtained from ClinicalTrials.gov on February 12, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Growth Disorders
Intervention: Growth hormone (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: Emory University Official(s) and/or principal investigator(s):
Lillian R. Meacham, MD, Principal Investigator, Affiliation: Children's Healthcare of Atlanta
Overall contact:
Melissa Hamilton, BS, Phone: 404-785-1717, Email: Melissa.Hamilton@choa.org
Summary
This is an observational research study (called a registry) for growth failure. The purpose
is to collect information on those who use Genentech growth hormone.
Clinical Details
Official title: Genentech National Cooperative Growth Study (NCGS) Post Marketing Surveillance Program for Nutropin AQ (Somatropin [rDNA Origin] Injection), Nutropin (Somatropin [rDNA Origin] for Injection) and Protropin (Somatrem for Injection)
Study design: Natural History, Cross-Sectional, Defined Population, Retrospective Study
Detailed description:
This is an observational research study (called a registry) for growth failure. The purpose
is to collect information on those who use Genentech growth hormone.
Eligibility
Minimum age: 18 Years.
Maximum age: 22 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Growth failure
Locations and Contacts
Melissa Hamilton, BS, Phone: 404-785-1717, Email: Melissa.Hamilton@choa.org
Children's Healthcare of Atlanta, Atlanta, Georgia 30322, United States; Recruiting
JoAnn Sadowski, BS, Phone: 404-785-3531, Email: Joann.Sadowski@choa.org
Lillian R. Meacham, MD, Principal Investigator
Additional Information
Starting date: August 2005
Last updated: December 13, 2006
|
